HC Wainwright Reiterates 'Buy' Rating for enGene (NASDAQ:ENGN)

enGene (NASDAQ:ENGN )'s stock had its 'buy' rating restated by analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $4.00 target price on the stock. HC Wainwright's price target suggests a potential upside of 112.20% from the stock's current price. Several other research firms have also weighed in on ENGN. Weiss Ratings reissued a 'sell (e+)' rating on shares of enGene in a research report on Wednesday, August 12th. Morgan Stanley lowered enGene from an 'equal weight' rating to an 'underweight' rating and set a $3.00 price target on the stock. in a research note on Thursday, June 18th. UBS Group lowered their price objective on shares of enGene from $9.00 to $2.00 and set a 'neutral' rating for the company in a research note on Thursday, May 14th. Finally, Wall Street Zen upgraded enGene from a 'strong sell' rating to a 'sell' rating in a research note on Saturday, August 15th. Four equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of 'Hold' and an average price target of $11.05. Read Our Latest Stock Report on ENGN enGene (NASDAQ:ENGN ) last released its quarterly earnings data on Tuesday, September 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.47). Analysts expect that enGene will post -1.84 EPS for the current year. A number of large investors have recently added to or reduced their stakes in ENGN. Cresset Asset Management LLC purchased a new position in shares of enGene during the 2nd quarter worth approximately $36,000. Paloma Partners Management Co bought a new stake in shares of enGene during the 2nd quarter valued at $38,000. Raymond James Financial Inc. increased its stake in shares of enGene by 383.6% in the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company's stock worth $68,000 after acquiring an additional 7,932 shares in the last quarter. Jump Financial LLC bought a new stake in enGene during the fourth quarter worth about $121,000. Finally, Millennium Management LLC lifted its holdings in shares of enGene by 57.3% during the third quarter. Millennium Management LLC now owns 20,502 shares of the company's stock valued at $140,000 after purchasing an additional 7,472 shares during the last quarter. Institutional investors own 64.16% of the company's stock. enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.